2月25日，东诚药业涨0.97%，成交额1.12亿元。两融数据显示，当日东诚药业获融资买入额1488.08万 元，融资偿还910.00万元，融资净买入578.08万元。截至2月25日，东诚药业融资融券余额合计10.75亿 元。 机构持仓方面，截止2025年12月31日，东诚药业十大流通股东中，香港中央结算有限公司位居第五大流 通股东，持股2027.93万股，相比上期增加25.21万股。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑：小浪快报 资料显示，烟台东诚药业集团股份有限公司位于山东省烟台经济技术开发区长白山路7号，成立日期 1998年12月31日，上市日期2012年5月25日，公司主营业务涉及肝素钠原料药、硫酸软骨素的研发、生 产和销售。主营业务收入构成为：原料药相关产品44.16%，核药产品36.38%，制剂产品13.17%，其他 6.30%。 截至9月30日，东诚药业股东户数2.46万，较上期增加4.51%；人均 ...

Core Viewpoint - Warner Pharmaceuticals reported a revenue of 1.516 billion yuan for the year 2025, marking a year-on-year growth of 7.26% and a net profit attributable to the parent company of 241 million yuan, which represents a significant increase of 46.95% [1] Revenue Growth - The increase in total revenue is attributed to the growth in sales of formulation products, active pharmaceutical ingredients, intermediates, and technical service income [1] Net Profit Analysis - The rise in net profit attributable to the parent company is primarily influenced by investment income [1] - However, the net profit excluding non-recurring gains and losses decreased due to the accrual of stock incentive expenses; after adjusting for these expenses, the net profit attributable to the parent company was 182 million yuan, reflecting a year-on-year increase of 31.57% [1]

Financial Data Summary - The company reported preliminary financial data for the year 2025, with total revenue of 1.516 billion yuan, representing a year-on-year increase of 7.26% [1] - The net profit attributable to the parent company was 241 million yuan, showing a significant year-on-year growth of 46.95% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 130 million yuan, which reflects a decrease of 6.01% compared to the previous year [1] - Total assets at the end of the reporting period reached 3.053 billion yuan, marking a year-on-year increase of 24.11% [1] - The equity attributable to the parent company was 2.046 billion yuan, up 13.44% year-on-year [1] Performance Drivers - The increase in revenue was primarily driven by growth in sales of formulation products, raw materials, intermediate products, and technical service income [2] - The rise in net profit attributable to the parent company was mainly influenced by investment income [2] - The decline in net profit after deducting non-recurring gains and losses was attributed to the impact of stock incentive expenses; excluding these expenses, the adjusted net profit would have been 182 million yuan, an increase of 31.57% year-on-year [2] Significant Changes in Financial Metrics - Operating profit increased by 51.53% year-on-year, while total profit rose by 51.88% [3] - The basic earnings per share grew by 47.20% year-on-year, largely due to the strategic investment and restructuring of Shanghai Zhigen Pharmaceutical Technology Co., Ltd., which resulted in the company no longer consolidating it in its financial statements [3] - The company's share capital increased by 40.00% due to a capital reserve conversion, raising the total shares from 93.8 million to 131.32 million [3]

Core Viewpoint - Warner Pharmaceutical (688799) reported a revenue of 1.516 billion yuan for the year 2025, reflecting a year-on-year growth of 7.26%, and a net profit attributable to shareholders of 241 million yuan, which represents a significant increase of 46.95% [1] Group 1 - The increase in revenue is attributed to growth in sales of formulation products, raw materials, intermediates, and technical service income [1] - The rise in net profit is primarily influenced by investment income [1]

Core Viewpoint - Warner Pharmaceuticals (688799.SH) reported a revenue of 1.516 billion yuan for the fiscal year 2025, representing a year-on-year growth of 7.26%, and a net profit attributable to the parent company of 241 million yuan, which is an increase of 46.95% [1] Revenue Summary - The revenue growth during the reporting period was primarily driven by increased sales of formulation products, active pharmaceutical ingredients, intermediate products, and growth in technical service income [1] Profit Summary - The increase in net profit attributable to the parent company was significantly influenced by investment income [1] - However, the net profit attributable to the parent company after deducting non-recurring gains and losses declined due to the impact of stock incentive expenses; excluding these expenses, the adjusted net profit was 182 million yuan, reflecting a year-on-year increase of 31.57% [1]

Core Viewpoint - Warner Pharmaceuticals (688799.SH) reported a revenue of 1.516 billion yuan for the fiscal year 2025, reflecting a year-on-year growth of 7.26%, and a net profit attributable to shareholders of 241 million yuan, which is a significant increase of 46.95% [1] Revenue Performance - The revenue growth during the reporting period was primarily driven by increased sales of formulation products, active pharmaceutical ingredients, intermediates, and growth in technical service income [1] Profit Analysis - The increase in net profit attributable to shareholders was mainly influenced by investment income; however, the net profit excluding non-recurring gains and losses declined due to the accrual of equity incentive expenses [1] - After excluding the impact of equity incentive expenses, the net profit attributable to shareholders, adjusted for non-recurring gains and losses, was 182 million yuan, representing a year-on-year increase of 31.57% [1]

Core Viewpoint - Warner Pharmaceuticals (688799.SH) reported a preliminary performance summary for the fiscal year 2025, indicating a revenue increase and significant growth in net profit, driven by various product sales and investment income [1] Financial Performance - The company achieved an operating revenue of 1.516 billion yuan, representing a year-on-year growth of 7.26% [1] - The net profit attributable to the parent company was 241 million yuan, showing a year-on-year increase of 46.95% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 130 million yuan, reflecting a year-on-year decline of 6.01% [1] Asset and Equity Growth - At the end of the reporting period, the total assets of the company reached 3.053 billion yuan, marking a year-on-year growth of 24.11% [1] - The equity attributable to the parent company was 2.046 billion yuan, which is a year-on-year increase of 13.44% [1] Revenue Drivers - The growth in operating revenue was primarily due to increased sales of formulation products, raw materials, intermediates, and technical service income [1] - The increase in net profit attributable to the parent company was mainly influenced by investment income [1] - The decline in net profit after deducting non-recurring gains and losses was attributed to the accrual of equity incentive expenses; excluding this impact, the adjusted net profit was 182 million yuan, which is a 31.57% increase compared to the same period last year [1]

Core Viewpoint - The company is focusing on internationalization as a long-term core development strategy, particularly targeting the EU market for product registration and market expansion [1] Group 1: Business Operations - Currently, the company's exports to the EU market primarily consist of raw materials, which represent a relatively small portion of the overall revenue [1] - Sales in the EU market are mainly conducted through a direct sales model with customers, supplemented by sales through distributors to ensure stable business progress [1] Group 2: Strategic Developments - The company has established a sales subsidiary in the Netherlands and is working on preparations for building a sales and registration system aimed at the EU market, in order to facilitate the future export of formulated products [1] - The company aims to continuously improve its global supply chain and sales layout to enhance its competitiveness in international markets [1]

Group 1 - The core viewpoint of the article highlights that Tianyu Co., Ltd. has officially launched its "annual production of 20,000 tons of high-purity solvent project," which has effectively improved capacity utilization [2] - The company continues to solidify its leading position in the raw material drug market for sartans, with significant results from its "raw materials + formulations" integrated strategy, leading to growth in both raw material drug revenue and formulation product revenue [2] - Several product varieties have obtained CEP certification or are in the process of FDA certification, with revenue from certified products expected to gradually materialize as the global market expands [2]

Core Viewpoint - The company has successfully completed the construction of a high-purity solvent project with an annual production capacity of 20,000 tons, which has effectively improved its capacity utilization rate [1] Group 1: Production and Capacity - The Changyi Tianyu project has officially commenced operations, leading to an increase in capacity utilization [1] - The company continues to solidify its position as a leading manufacturer of sartans, with a significant focus on the integration of raw materials and formulations [1] Group 2: Market Position and Revenue - The company's revenue from both raw materials and formulation products is showing a growth trend [1] - Several products have obtained CEP certification or are actively pursuing FDA certification, with revenue contributions expected to materialize as global market expansion progresses [1]